Page
|
|
Part
I – FINANCIAL INFORMATION
|
|
Item
1. Condensed Consolidated Financial Statements
(unaudited)
|
|
2
|
|
3
|
|
4
|
|
5
|
|
6
|
|
7
|
|
11
|
|
PART
II – OTHER INFORMATION
|
|
14
|
|
14
|
Three months ended
September 30,
|
||||||||
2009
|
2010
|
|||||||
Revenue:
|
||||||||
License
and research revenue
|
$ | 4,726 | $ | 4,119 | ||||
Product
sales and services
|
2,651 | 1,805 | ||||||
Other
revenues
|
2,521 | 2,117 | ||||||
Total
revenue
|
9,898 | 8,041 | ||||||
Costs
and expenses:
|
||||||||
Cost
of goods and services sold
|
(2,567 | ) | (1,535 | ) | ||||
Research
and development
|
(7,531 | ) | (6,702 | ) | ||||
Selling,
general and administrative
|
(3,138 | ) | (2,931 | ) | ||||
Total
|
(13,236 | ) | (11,168 | ) | ||||
Loss
from operations
|
(3,338 | ) | (3,127 | ) | ||||
Interest
income net
|
92 | 109 | ||||||
Foreign
exchange gain (loss)
|
(140 | ) | (302 | ) | ||||
Other
income
|
4 | 5 | ||||||
Loss
before income taxes
|
(3,382 | ) | (3,315 | ) | ||||
Income
tax benefit (expense)*
|
- | (24 | ) | |||||
Net
loss
|
$ | (3,382 | ) | $ | (3,339 | ) | ||
Loss
per share
|
||||||||
Basic
loss per ordinary share
|
$ | (0.14 | ) | $ | (0.14 | ) | ||
Diluted
loss per share
|
$ | (0.14 | ) | $ | (0.14 | ) | ||
Weighted
average number of shares outstanding (in thousands) :
|
||||||||
Basic
|
24,225 | 24,423 | ||||||
Diluted
|
24,225 | 24,423 |
Nine months ended
September 30,
|
||||||||
2009
|
2010
|
|||||||
Revenue:
|
||||||||
License
and research revenue
|
$ | 16,156 | $ | 10,865 | ||||
Product
sales and services
|
7,602 | 5,970 | ||||||
Other
revenues
|
7,769 | 6,808 | ||||||
Total
revenue
|
31,527 | 23,643 | ||||||
Costs
and expenses:
|
||||||||
Cost
of goods and services sold
|
(6,508 | ) | (5,045 | ) | ||||
Research
and development
|
(21,464 | ) | (21,824 | ) | ||||
Selling,
general and administrative
|
(9,371 | ) | (8,659 | ) | ||||
Total
|
(37,343 | ) | (35,528 | ) | ||||
Loss
from operations
|
(5,816 | ) | (11,885 | ) | ||||
Interest
income net
|
349 | 326 | ||||||
Foreign
exchange gain (loss)
|
(288 | ) | (87 | ) | ||||
Other
income
|
13 | 93 | ||||||
Loss
before income taxes
|
(5,742 | ) | (11,553 | ) | ||||
Income
tax benefit (expense)*
|
- | (100 | ) | |||||
Net
loss
|
$ | (5,742 | ) | $ | (11,653 | ) | ||
Loss
per share
|
||||||||
Basic
loss per ordinary share
|
$ | (0.24 | ) | $ | (0.48 | ) | ||
Diluted
loss per share
|
$ | (0.24 | ) | $ | (0.48 | ) | ||
Weighted
average number of shares outstanding (in thousands):
|
||||||||
Basic
|
24,217 | 24,391 | ||||||
Diluted
|
24,217 | 24,391 |
December31,
2009
|
September
30,
2010
|
|||||||
ASSETS
|
||||||||
Current
assets:
|
||||||||
Cash
and cash equivalents
|
$ | 8,716 | $ | 3,909 | ||||
Marketable
securities
|
35,352 | 28,132 | ||||||
Accounts
receivable
|
8,675 | 10,227 | ||||||
Inventory
|
1,072 | 1,070 | ||||||
Research
and development tax credit receivable short term
|
9,400 | 2,353 | ||||||
Prepaid
expenses and other current assets
|
3,626 | 4,555 | ||||||
Total
current assets
|
66,841 | 50,246 | ||||||
Property
and equipment, net
|
24,759 | 22,677 | ||||||
Other
assets:
|
||||||||
Research
and development tax credit receivable long term
|
2,484 | 4,272 | ||||||
Other
long-term assets
|
212 | 189 | ||||||
Total
other assets
|
2,696 | 4,461 | ||||||
Total
assets
|
$ | 94,296 | $ | 77,384 | ||||
LIABILITIES
|
||||||||
Current
liabilities:
|
||||||||
Current
portion of long-term debt
|
862 | 2,158 | ||||||
Current
portion of capital lease obligations
|
33 | 34 | ||||||
Accounts
payable
|
6,366 | 5,156 | ||||||
Current
portion of deferred revenue
|
3,862 | 2,529 | ||||||
Advances
from customers
|
851 | 4,488 | ||||||
Accrued
expenses
|
6,318 | 5,974 | ||||||
Other
current liabilities
|
4,604 | 4,023 | ||||||
Total
current liabilities
|
22,896 | 24,362 | ||||||
Long-term
debt, less current portion
|
2,944 | 1,789 | ||||||
Capital
lease obligations, less current portion
|
66 | 35 | ||||||
Deferred
revenue, less current portion
|
6,033 | 3,715 | ||||||
Other
long-term liabilities
|
17,494 | 14,015 | ||||||
Total
long-term liabilities
|
26,537 | 19,554 | ||||||
Commitments
and contingencies:
|
- | - | ||||||
Shareholders'
equity:
|
||||||||
Ordinary
shares: 24,342,600 issued and outstanding at December 31, 2009 and
24,422,600 at September 30, 2010 (shares authorised 29,650,790) at nominal
value of 0.122 euro
|
3,540 | 3,553 | ||||||
Additional
paid-in capital
|
198,498 | 201,571 | ||||||
Accumulated
deficit
|
(171,644 | ) | (183,297 | ) | ||||
Accumulated
other comprehensive income (loss)
|
14,469 | 11,641 | ||||||
Total
shareholders' equity
|
44,863 | 33,468 | ||||||
Total
liabilities and shareholders' equity
|
$ | 94,296 | $ | 77,384 |
Nine months ended September 30,
|
||||||||
2009
|
2010
|
|||||||
Cash
flows from operating activities:
|
||||||||
Net
income (loss)
|
$ | (5,742 | ) | $ | (11,653 | ) | ||
Adjustments
to reconcile net income (loss)
|
||||||||
to
net cash provided by (used in) operating activities:
|
||||||||
Depreciation
of property and equipment
|
4,080 | 3,525 | ||||||
Gains
on sales of marketable securities
|
(118 | ) | (59 | ) | ||||
Grants
recognized in other income and income from operations
|
(782 | ) | (828 | ) | ||||
Stock
compensation expense
|
4,314 | 2,328 | ||||||
Increase
(decrease) in cash from:
|
||||||||
Accounts
receivable
|
238 | (1,843 | ) | |||||
Inventory
|
(169 | ) | (36 | ) | ||||
Prepaid
expenses and other current assets
|
(697 | ) | (315 | ) | ||||
Research
and development tax credit receivable
|
5,738 | 4,355 | ||||||
Accounts
payable
|
(732 | ) | (382 | ) | ||||
Deferred
revenue
|
8,039 | (3,015 | ) | |||||
Accrued
expenses
|
90 | 3,447 | ||||||
Other
current liabilities
|
2,360 | (298 | ) | |||||
Other
long-term assets and liabilities
|
(2,909 | ) | (671 | ) | ||||
Net
cash provided by (used in) operating activities
|
13,710 | (5,445 | ) | |||||
Cash
flows from investing activities:
|
||||||||
Purchases
of property and equipment
|
(1,532 | ) | (3,253 | ) | ||||
Purchase
of marketable securities
|
(131,347 | ) | (65,705 | ) | ||||
Proceeds
from sales of marketable securities
|
100,651 | 70,727 | ||||||
Net
cash provided by (used in) investing activities
|
(32,228 | ) | 1,769 | |||||
Cash
flows from financing activities:
|
||||||||
Proceeds
from loans or conditional grants
|
520 | 318 | ||||||
Reimbursement
of loans or conditional grants
|
(3,998 | ) | (1,879 | ) | ||||
Principal
payments on capital lease obligations
|
(60 | ) | (24 | ) | ||||
Cash
proceeds from issuance of ordinary shares and warrants
|
291 | 627 | ||||||
Net
cash provided by (used in) financing activities
|
(3,247 | ) | (958 | ) | ||||
Effect
of exchange rate changes on cash and cash equivalents
|
(472 | ) | (173 | ) | ||||
Net
increase (decrease) in cash and cash equivalents
|
(22,237 | ) | (4,807 | ) | ||||
Cash
and cash equivalents, beginning of period
|
27,021 | 8,716 | ||||||
Cash
and cash equivalents, end of period
|
$ | 4,784 | $ | 3,909 |
Ordinary
Shares
|
Additional
|
Accumulated
Other
Comprehen-
|
||||||||||||||||||||||
Shares
|
Amount
|
Paid-in
Capital
|
Accumulated
Deficit
|
sive
Income
(Loss)
|
Shareholders'
Equity
|
|||||||||||||||||||
Balance
at January 1, 2010
|
24,342,600 | $ | 3,540 | $ | 198,498 | $ | (171,644 | ) | $ | 14,469 | $ | 44,863 | ||||||||||||
Subscription
of warrants
|
224 | 224 | ||||||||||||||||||||||
Issuance
of ordinary shares on exercise of stock -options
|
40,000 | 7 | 396 | 403 | ||||||||||||||||||||
Issuance
of ordinary shares on vesting of free shares
|
40,000 | 6 | (6 | ) | - | |||||||||||||||||||
Stock-based
compensation expense
|
2,459 | 2,459 | ||||||||||||||||||||||
Net
loss
|
(11,653 | ) | (11,653 | ) | ||||||||||||||||||||
Foreign
currency translation adjustment
|
(2,828 | ) | (2,828 | ) | ||||||||||||||||||||
Comprehensive
loss
|
$ | (14,481 | ) | |||||||||||||||||||||
Balance
at September 30, 2010
|
24,422,600 | $ | 3,553 | $ | 201,571 | $ | (183,297 | ) | $ | 11,641 | $ | 33,468 |
Three months ended
September 30, 2010
|
||||
Risk-free
interest rate
|
0.95 | % | ||
Dividend
yield
|
- | |||
Expected
volatility
|
62 | % | ||
Expected
term
|
2.9
years
|
|||
Forfeiture
rate
|
- |
Three months ended
|
Nine months ended
|
|||||||||||||||
(in thousands except per share data)
|
September
30, 2009
|
September
30, 2010
|
September
30, 2009
|
September
30, 2010
|
||||||||||||
Net
income (loss)
|
(3,382 | ) | (3,339 | ) | (5,742 | ) | (11,653 | ) | ||||||||
Net
income (loss) per share
|
||||||||||||||||
Basic
|
$ | (0.14 | ) | $ | (0.14 | ) | $ | (0.24 | ) | $ | (0.48 | ) | ||||
Diluted
|
$ | (0.14 | ) | $ | (0.14 | ) | $ | (0.24 | ) | $ | (0.48 | ) | ||||
Number
of shares used for computing
|
||||||||||||||||
Basic
|
24,225 | 24,423 | 24,217 | 24,391 | ||||||||||||
Diluted
|
24,225 | 24,423 | 24,217 | 24,391 | ||||||||||||
Stock-based
compensation (ASC718)
|
||||||||||||||||
Cost of products and services sold
|
60 | 31 | 171 | 95 | ||||||||||||
Research and development
|
565 | 293 | 1,791 | 874 | ||||||||||||
Selling, general and administrative
|
851 | 399 | 2,351 | 1,359 | ||||||||||||
Total
|
1,476 | 723 | 4,313 | 2,328 | ||||||||||||
Net
income (loss) before stock-based compensation
|
(1,906 | ) | (2,616 | ) | (1,429 | ) | (9,325 | ) | ||||||||
Net
income (loss) before stock-based compensation per share
|
||||||||||||||||
Basic
|
$ | (0.08 | ) | $ | (0.11 | ) | $ | (0.06 | ) | $ | (0.38 | ) | ||||
Diluted
|
$ | (0.08 | ) | $ | (0.11 | ) | $ | (0.06 | ) | $ | (0.38 | ) |
-
|
a
cash outflow from financing activities of $1.9 million, related to the
reimbursement to OSEO for the
advance OSEO provided
secured against the research tax credit from 2006,
and
|
-
|
a cash inflow from
operating activities of $2.3 million, corresponding to the research tax
credit from 2006 paid by the tax authorities (and a corresponding
decrease in the amount of the research tax credit
receivable).
|
|
·
|
sales of products that
incorporate our drug delivery
technologies;
|
|
·
|
financial terms of collaborative,
technology access, license or other commercial agreements we enter
into;
|
|
·
|
results of research and
development efforts;
|
|
·
|
technological advances;
and
|
|
·
|
results of clinical testing,
requirements of the US Food and Drug Administration (FDA) and comparable
foreign regulatory agencies.
|
|
·
|
we
depend on a few customers for the majority of our revenues, and the loss
of any one of these customers could reduce our revenues
significantly;
|
|
·
|
our
revenues depend on pharmaceutical and biotechnology companies successfully
developing products that incorporate our drug delivery
technologies;
|
|
·
|
although
products that incorporate our drug delivery technologies may appear
promising at their early stages of development and in clinical trials,
none of these potential products may reach the commercial market for a
number of reasons;
|
|
·
|
we
must invest substantial sums in research and development in order to
remain competitive, and we may not fully recover these
investments;
|
|
·
|
we
depend upon a single site to manufacture our products, and any
interruption of operations could have a material adverse effect on our
business;
|
|
·
|
we
depend on a limited number of suppliers for certain raw materials used in
our products, and any failure to deliver sufficient supplies could
interrupt our production process and could have a material adverse affect
on our business;
|
|
·
|
we
depend on key personnel to execute our business plan; if we cannot
attract and retain key personnel, we may not be able to successfully
implement our business plan;
|
|
·
|
if
our competitors develop and market drug delivery technologies or related
products that are more effective than ours, or obtain regulatory approval
and market such technology or products before we do, our commercial
opportunity will be diminished or
eliminated;
|
|
·
|
if
we cannot keep pace with the rapid technological change in our industry,
we may lose business, and our drug delivery systems could become obsolete
or noncompetitive;
|
|
·
|
if
we cannot adequately protect our technology and proprietary information,
we may be unable to sustain a competitive
advantage;
|
|
·
|
our
products and technologies may not gain market
acceptance;
|
|
·
|
if
we or our collaborative partners are required to obtain licenses from
third parties, our revenues and royalties on any commercialized products
could be reduced;
|
|
·
|
if
our third party collaborative partners face generic competition for their
products, our revenues and royalties from such products may be adversely
affected;
|
|
·
|
healthcare
reform and restrictions on reimbursements may limit our financial
returns;
|
|
·
|
ongoing
current credit and financial market conditions may exacerbate certain
risks affecting our business;
|
|
·
|
fluctuations
in foreign currency exchange rates may cause fluctuations in our financial
results;
|
|
·
|
products
that incorporate our drug delivery technologies are subject to regulatory
approval; if our pharmaceutical and biotechnology company partners do not
obtain such approvals, or if such approvals are delayed, our revenues may
be adversely affected;
|
|
·
|
commercial
products incorporating our technologies are subject to continuing
regulation, and we and our pharmaceutical and biotechnology company
partners may be subject to adverse consequences if we or they fail to
comply with applicable regulations;
|
|
·
|
regulatory
reforms may adversely affect our ability to sell our products
profitably;
|
|
·
|
certain
companies to which we have licensed our technology are subject to
extensive regulation by the FDA and other regulatory authorities,
their failure to meet strict regulatory requirements could adversely
affect our business;
|
|
·
|
we
may face product liability claims related to participation in clinical
trials or the use or misuse of our products or products that incorporate
our technologies;
|
|
·
|
third
parties have claimed, and may claim in the future, that our technologies,
or the products in which they are used, infringe on their rights and we
may incur significant costs resolving these
claims;
|
|
·
|
if
we use biological and hazardous materials in a manner that causes injury,
we may be liable for significant
damages;
|
|
·
|
our
share price has been volatile and may continue to be
volatile;
|
|
·
|
because
we have a limited operating history, investors in our shares may have
difficulty evaluating our
prospects;
|
|
·
|
if
we are not profitable in the future, the value of our shares may
fall;
|
|
·
|
we
may require additional financing, which may not be available on favorable
terms or at all, particularly in light of the slow global economic
recovery and its negative effect on the capital markets, and which
may result in dilution of our shareholders’ equity
interest;
|
|
·
|
our
operating results may fluctuate, which may adversely affect our share
price;
|
|
·
|
we
are subject to different corporate disclosure standards that may limit the
information available to holders of our
ADSs;
|
|
·
|
we
currently do not intend to pay dividends, and cannot assure shareholders
that we will make dividend payments in the
future;
|
|
·
|
judgments
of United States courts, including those predicated on the civil liability
provisions of the federal securities laws of the United States, may not be
enforceable in French courts;
|
|
·
|
holders
of ADSs have fewer rights than shareholders and have to act through the
Depositary to exercise those
rights;
|
|
·
|
preferential
subscription rights may not be available for United States persons;
and
|
|
·
|
our
largest shareholders own a significant percentage of the share capital and
voting rights of the Company;
|
Flamel
Technologies, S.A.
|
|
Dated:
January 21, 2011
|
/s/ Stephen H. Willard
|
Stephen
H. Willard
|
|
Chief
Executive Officer
|